Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA

NCT01179217 is registered in ClinicalTrials.gov with Emmaus Medical, Inc. as lead sponsor.

NCT NCT01179217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01179217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA
Lead sponsor
Emmaus Medical, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2010
Completion date
March 31, 2014
Enrollment
230 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia, sickle ß0-thalassemia